arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CAPRICOR THERAPEUTICS, INC.

CAPR
$8.68 ▼ -0.66 (-7.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
81 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

CAPRICOR THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $502.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -17.4%
FCF / Share $-0.61
Trailing P/E
Price / Book 2.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

81-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.13M
↓ -7.9%
Net Income Profit after all expenses
$-33.94M
↓ -39.2%
Operating Margin Operating profit as % of sales
-69.1%
↑ +76.3%
FCF / Share Free cash flow per share
$-0.61
↓ -37.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 21 years · 81 quarters